Comprehensive mapping of immune perturbations associated with severe COVID-19
Open accessThe DOI matches its Crossref record; 119 of the 119 references it cites were found in a registry or an index.
Abstract
Profound plasmablast expansion, innate cell modulation, and T cell activation are defining features of severe COVID-19.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We believe that the features described herein may help to identify the immunopathology of similar illnesses, such as irAEs and CRS due to other immunotherapies (e.g. checkpoint inhibitors, CAR-T-cells) or COVID-19 [4, 18, 19], and to inform discussions on the type and length of clinical and immune monitoring warranted in such patients.”
From Immune reconstitution and clinical recovery following anti-CD28 antibody (TGN1412)-induced cytokine storm (2021) · cites this paper as [19]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical–pathologic correlation in these individuals resulted in valuable observations that may be instructive in understanding mechanisms of immune-induced pathologies, including those of checkpoint inhibitors, CAR-T cells, and infections such as COVID-19, known to target mucosal tissues and cause severe CRS [1, 5, 8, 18, 19].”
From Immune reconstitution and clinical recovery following anti-CD28 antibody (TGN1412)-induced cytokine storm (2021) · cites this paper as [19]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“suggesting the lung as a source for the elevated plasma levels of type I IFNs early on infection”
From COVID-19 and the human innate immune system (2021) · cites this paper as Kuri-Cervantes et al., 2020
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Ineffective IFN innate immunity has been strongly associated with failure to control a primary SARS-CoV-2 infection and a high risk of fatal COVID-19, accompanied by innate cell immunopathology and a plasma cytokine signature of elevated CXCL10, interleukin (IL)-6, and IL-8 in many studies (Aid et al., 2020; Kuri-Cervantes et al., 2020; Li et al., 2020b; Lucas et al., 2020; Radermecker et al., 202”
From Adaptive immunity to SARS-CoV-2 and COVID-19 (2021) · cites this paper as Kuri-Cervantes et al., 2020
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“particularly observation of elevated frequencies of neutrophils (the most common cell type of the innate immune system) in blood (Kuri-Cervantes et al., 2020), and massive numbers of neutrophils in lungs, associated with severe, end-stage COVID-19 disease (Li et al., 2020b; Liao et al., 2020; Radermecker et al., 2020; Schurink et al., 2020). In contrast, end-stage disease is not generally”
From Adaptive immunity to SARS-CoV-2 and COVID-19 (2021) · cites this paper as Kuri-Cervantes et al., 2020
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Wang, X., Xu, W., Hu, G., Xia, S., Sun, Z., Liu, Z., Xie, Y., Zhang, R., Jiang, S., & Lu, L. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-0498-4 · Cited by 175
RetractedWang, X., Xu, W., Hu, G., Xia, S., Sun, Z., Liu, Z., Xie, Y., Zhang, R., Jiang, S., & Lu, L. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-0424-9 · Cited by 161
RetractedClinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
Clinical characteristics of coronavirus disease 2019 in China
Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D. S. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002032 · Cited by 30,246
Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Wang, J., Liu, Y., Wei, Y., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30211-7 · Cited by 21,415
Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., et al. (2020) · JAMA · doi:10.1001/jama.2020.1585 · Cited by 20,148
La certeza de lo impredecible: Cultura Educación y Sociedad en tiempos de COVID19
Martínez González, M. (2020) · DSPACE System - Metalibrary (University of the Coast) · Cited by 18,463
Martínez–González, M. B. (2020) · DSPACE System - Metalibrary (University of the Coast) · Cited by 18,296
Binary Codes capable of currecting deletions, insertions, and reversals
Levenshtein, V. I. (1965) · Soviet physics. Doklady · Cited by 14,807
Chen, Y., Wang, L., Kang, Q., Zhang, X., Yu, G., Wan, X., Wang, J., & Zhu, K. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000477308 · Cited by 10,679
Research works printed but not linked: 2
- WHO Novel Coronavirus 2019 Reports (World Health Organization 2020) vol. 2020.
- 10.1146/annurev.iy.13.040195.001015 · doi:10.1146/annurev.iy.13.040195.001015 · Paper page
Cited by
Items 101–200 of 761
The immunology of SARS-CoV-2 infections and vaccines
Grigoryan, L., & Pulendran, B. (2020) · Seminars in Immunology · doi:10.1016/j.smim.2020.101422 · Cited by 111
Immunological imprint of COVID‐19 on human peripheral blood leukocyte populations
Kratzer, B., Trapin, D., Ettel, P., Körmöczi, U., Rottal, A., Tuppy, F., Feichter, M., Gattinger, P., Borochova, K., Dorofeeva, Y., et al. (2020) · Allergy · doi:10.1111/all.14647 · Cited by 106
The Surviving Sepsis Campaign: Research Priorities for Coronavirus Disease 2019 in Critical Illness
Coopersmith, C. M., Antonelli, M. M., Bauer, S. R., Deutschman, C. S., Evans, L., Ferrer, R., Hellman, J., Jog, S., Kesecioğlu, J., Kissoon, N. “., et al. (2021) · Critical Care Medicine · doi:10.1097/ccm.0000000000004895 · Cited by 118
Self-supervised contrastive learning for integrative single cell RNA-seq data analysis
Han, W., Cheng, Y., Chen, J., Zhong, H., Hu, Z., Chen, S., Zong, L., Hong, L., Chan, T., King, I., et al. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac377 · Cited by 110
Turtle, L. C. W., Thorpe, M., Drake, T. M., Swets, M. C., Palmieri, C., Russell, C. D., Ho, A. Y. W., Aston, S., Wootton, D. G., Richter, A., et al. (2023) · PLoS Medicine · doi:10.1371/journal.pmed.1004086 · Cited by 105
B-cell and antibody responses to SARS-CoV-2: infection, vaccination, and hybrid immunity
Lapuente, D., Winkler, T., & Tenbusch, M. (2023) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-01095-w · Cited by 111
Casciola-Rosen, L. A., Thiemann, D. R., Andrade, F., Trejo‐Zambrano, M. I., Leonard, E. K., Spangler, J. B., Skinner, N., Bailey, J. R., Yegnasubramanian, S., Wang, R., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.158362 · Cited by 98
Channappanavar, R., & Perlman, S. M. (2020) · Journal of Clinical Investigation · doi:10.1172/jci144115 · Cited by 98
SARS-CoV-2 induces robust germinal center CD4 T follicular helper cell responses in rhesus macaques
Lakshmanappa, Y. S., Elizaldi, S. R., Roh, J. W., Schmidt, B., Carroll, T. D., Weaver, K. D., Smith, J. C., Verma, A., Deere, J. D., Dutra, J., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20642-x · Cited by 96
Durable SARS-CoV-2 B cell immunity after mild or severe disease
Ogega, C. O., Skinner, N., Blair, P. W., Park, H.-S., Littlefield, K. E., Ganesan, A., Dhakal, S., Ladiwala, P., Antar, A. A. R., Ray, S. C., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci145516 · Cited by 99
Immunology, immunopathogenesis and immunotherapeutics of COVID-19; an overview
Khosroshahi, L. M., Rokni, M., Mokhtari, T., & Noorbakhsh, F. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107364 · Cited by 94
Javed, H., Meeran, M. F. N., Jha, N. K., & Ojha, S. K. (2021) · Frontiers in Plant Science · doi:10.3389/fpls.2020.601335 · Cited by 95
Impaired function and delayed regeneration of dendritic cells in COVID-19
Winheim, E., Rinke, L., Lutz, K., Reischer, A., Leutbecher, A., Wolfram, L., Rausch, L., Kranich, J., Wratil, P. R., Huber, J. E., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009742 · Cited by 100
Won, T., Wood, M. K., Hughes, D. M., Talor, M. V., Ma, Z., Schneider, J., SKINNER, J. T., Asady, B., Goerlich, E., Halushka, M. K., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103812 · Cited by 93
Haemophagocytic syndrome and COVID-19
Retamozo, S., Brito‐Zerón, P., Sisó‐Almirall, A., Flores-Chávez, A., Cárdenas, M. J. S., & Ramos‐Casals, M. (2021) · Clinical Rheumatology · doi:10.1007/s10067-020-05569-4 · Cited by 93
Erythrocytes identify complement activation in patients with COVID-19
Lam, L., Reilly, J. P., Rux, A. H., Murphy, S. J., Kuri-Cervantes, L., Weisman, A. R., Ittner, C. A. G., Pampena, M. B., Betts, M. R., Wherry, E. J., et al. (2021) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00231.2021 · Cited by 95
Self-citationNeutrophils and COVID-19: Active Participants and Rational Therapeutic Targets
Hazeldine, J., & Lord, J. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.680134 · Cited by 89
Fahlberg, M. D., Blair, R. V., Doyle‐Meyers, L. A., Midkiff, C. C., Zenere, G., Russell‐Lodrigue, K., Monjure, C. J., Haupt, E., Penney, T., Lehmicke, G., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19967-4 · Cited by 94
Innate lymphoid cell composition associates with COVID‐19 disease severity
García, M., Kokkinou, E., García, A. C., Parrot, T., Medina, L. M. P., Maleki, K. T., Christ, W., Varnaitė, R., Filipovic, I., Ljunggren, H., et al. (2020) · Clinical & Translational Immunology · doi:10.1002/cti2.1224 · Cited by 88
Varghese, P. M., Tsolaki, A. G., Yasmin, H., Shastri, A., Ferluga, J., Vatish, M., Madan, T., & Kishore, U. (2020) · Immunobiology · doi:10.1016/j.imbio.2020.152008 · Cited by 89
Profiling of immune dysfunction in COVID-19 patients allows early prediction of disease progression
Rendeiro, A. F., Casano, J., Vorkas, C. K., Singh, H. K., Morales, A. E., Desimone, R. A., Ellsworth, G. B., Soave, R., Kapadia, S. N., Saito, K., et al. (2020) · Life Science Alliance · doi:10.26508/lsa.202000955 · Cited by 86
Characterization of low-density granulocytes in COVID-19
Cabrera, L. E., Pekkarinen, P. T., Alander, M., Nowlan, K., Nguyen, N.-A. A., Jokiranta, S. T., Kuivanen, S. H., Patjas, A., Mero, S., Pakkanen, S. H., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009721 · Cited by 91
Hematopoietic responses to SARS-CoV-2 infection
Elahi, S. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04220-6 · Cited by 84
The pathogenesis of coronavirus-19 disease
Borczuk, A., & Yantiss, R. K. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00872-5 · Cited by 88
Cellular Immune Response to COVID-19 and Potential Immune Modulators
Zhou, X. K., & Ye, Q. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.646333 · Cited by 80
The role of B cells in COVID-19 infection and vaccination
Chen, S., Guan, F., Candotti, F., Benlagha, K., Câmara, N. O. S., Herrada, A. A., James, L. K., Lei, J., Miller, H., Kubo, M., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.988536 · Cited by 86
Anderson, E. M., Diorio, C. J., Goodwin, E. C., McNerney, K. O., Weirick, M. E., Gouma, S., Bolton, M. J., Arevalo, C. P., Chase, J. M., Hicks, P. D., et al. (2020) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piaa161 · Cited by 74
Self-citationHLA-DR Marks Recently Divided Antigen-Specific Effector CD4 T Cells in Active Tuberculosis Patients
Tippalagama, R., Singhania, A., Dubelko, P., Arlehamn, C. S. L., Crinklaw, A., Pomaznoy, M., Seumois, G., Silva, A. D. D., Premawansa, S., Vidanagama, D. S., et al. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2100011 · Cited by 88
Boroujeni, M. E., Sekrecka, A., Antonczyk, A., Hassani, S., Sekrecki, M., Nowicka, H., Łopacinska, N., Olya, A., Kluzek, K., Wesoły, J., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.888897 · Cited by 78
Functions of double‐negative B cells in autoimmune diseases, infections, and cancers
Chung, M. K. Y., Gong, L., Kwong, D. L., Lee, V. H., Lee, A. W., Guan, X., Kam, N., & Dai, W. (2023) · EMBO Molecular Medicine · doi:10.15252/emmm.202217341 · Cited by 73
White Blood Cells and Severe COVID-19: A Mendelian Randomization Study
Sun, Y., Zhou, J., & Ye, K. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11030195 · Cited by 82
Innate lymphoid cells and COVID-19 severity in SARS-CoV-2 infection
Silverstein, N. J., Wang, Y., Manickas-Hill, Z., Carbone, C., Dauphin, A., Boribong, B. P., Loiselle, M., Davis, J., Leonard, M. M., Kuri-Cervantes, L., et al. (2022) · eLife · doi:10.7554/elife.74681 · Cited by 79
Self-citationEffective Immune Functions of Micronutrients against SARS-CoV-2
Junaid, K., Ejaz, H., Abdalla, A. E., Abosalif, K. O. A., Ullah, M. I., Yasmeen, H., Younas, S., Hamam, S. S. M., & Rehman, A. (2020) · Nutrients · doi:10.3390/nu12102992 · Cited by 82
COVID-19 Pathogenesis and Clinical Manifestations
Acosta, R. A. H., Garrigos, Z. E., Marcelin, J. R., & Vijayvargiya, P. (2022) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2022.01.003 · Cited by 79
Newell, K. L., Clemmer, D. C., Cox, J. B., Kayode, Y. I., Zoccoli-Rodriguez, V., Taylor, H. E., Endy, T. P., Wilmore, J. R., & Winslow, G. M. (2021) · PLoS ONE · doi:10.1371/journal.pone.0244855 · Cited by 78
Antunes, R. D. S., Pallikkuth, S., Williams, E., Yu, E. D., Mateus, J., Quiambao, L. G., Wang, E. W., Rawlings, S. A., Stadlbauer, D., Jiang, K., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab176 · Cited by 76
Rhoades, N. S., Pinski, A. N., Monsibais, A. N., Jankeel, A., Doratt, B. M., Cinco, I. R., Ibraim, I. C., & Messaoudi, I. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109637 · Cited by 78
Role of Senescence and Aging in SARS-CoV-2 Infection and COVID-19 Disease
Lynch, S. M., Guo, G., Gibson, D. S., Bjourson, A. J., & Singh, T. (2021) · Cells · doi:10.3390/cells10123367 · Cited by 75
Understanding NK cell biology for harnessing NK cell therapies: targeting cancer and beyond
Shin, E., Bak, S. H., Park, T., Kim, J.-W., Yoon, S. R., Jung, H., & Noh, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1192907 · Cited by 79
Self-citationMunker, D., Osterman, A., Stubbe, H. C., Muenchhoff, M., Veit, T., Weinberger, T., Barnikel, M., Mumm, J., Milger, K., Khatamzas, E., et al. (2021) · European Respiratory Journal · doi:10.1183/13993003.02724-2020 · Cited by 69
Duration of post–COVID-19 symptoms is associated with sustained SARS-CoV-2–specific immune responses
Files, J. K., Sarkar, S., Fram, T., Boppana, S., Sterrett, S., Qin, K., Bansal, A., Long, D. M., Sabbaj, S., Kobie, J. J., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.151544 · Cited by 83
Al‐Nesf, M. A., Abdesselem, H., Bensmail, I., Ibrahim, S. I., Saeed, W., Mohammed, S., Razok, A., Alhussain, H., Aly, R. M. A., Maslamani, M. A. R. S. A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28639-4 · Cited by 72
Hallmarks of immune response in COVID-19: Exploring dysregulation and exhaustion
Mazzoni, A., Salvati, L., Maggi, L., Annunziato, F., & Cosmi, L. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101508 · Cited by 80
Cytokine Storm Signature in Patients with Moderate and Severe COVID-19
Kalinina, O., Головкин, А. С., Zaikova, E. K., Aquino, A. D., Bezrukikh, V. A., Melnik, O., Vasilieva, E. Y., Каронова, Т. Л., Kudryavtsev, I. V., & Shlyakhto, E. V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23168879 · Cited by 73
Cell deaths: Involvement in the pathogenesis and intervention therapy of COVID-19
Li, X., Zhang, Z., Wang, Z., Gutiérrez-Castrellón, P., & Shi, H. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01043-6 · Cited by 67
“The decreased proportion of dendritic cells (DCs) in COVID-19 patients is another immune feature, which also correlates with the disease severity of SARS-CoV-2 infection.(56,63,64) Damaged mitochondria and caspase-3 activation-dependent apoptosis were found in monocyte-derived macrophages (MDMs) and DCs, which could b…”
BackgroundImmunosenescence and inflamm-ageing in COVID-19
Zinatizadeh, M. R., Zarandi, P. K., Ghiasi, M., Kooshki, H., Mohammadi, M., Amani, J., & Rezaei, N. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101818 · Cited by 77
Defending against SARS-CoV-2: The T cell perspective
Almendro-Vázquez, P., Laguna‐Goya, R., & Paz‐Artal, E. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1107803 · Cited by 76
T-cell dysregulation in COVID-19
Kalfaoglu, B., Almeida‐Santos, J., Tye, C. A., Satou, Y., & Lab), M. O. (. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.10.079 · Cited by 73
The Future of Blood Testing Is the Immunome
Arnaout, R., Prak, E. T. L., Schwab, N., Rubelt, F., & Community, T. A. I. R. R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.626793 · Cited by 69
Lorè, N. I., LORENZO, R. D., Rancoita, P. M. V., Cugnata, F., Agresti, A., Benedetti, F., Bianchi, M. E., Bonini, C., Capobianco, A., Conte, C., et al. (2021) · Molecular Medicine · doi:10.1186/s10020-021-00390-4 · Cited by 69
T cell immune memory after covid-19 and vaccination
Wang, L., Nicols, A. R., Turtle, L. C. W., Richter, A. G., Duncan, C. J. A., Dunachie, S. J., Klenerman, P., & Payne, R. (2023) · BMJ Medicine · doi:10.1136/bmjmed-2022-000468 · Cited by 72
Wildner, N. H., Ahmadi, P., Schulte, S., Brauneck, F., Kohsar, M., Lütgehetmann, M., Beisel, C., Addo, M. M., Haag, F., & Wiesch, J. S. Z. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.5cova0620-370rr · Cited by 66
Bonnet, B., Cosme, J., Dupuis, C., Coupez, E., Adda, M., Calvet, L., Fabre, L., Saint-Sardos, P., Bereiziat, M., Vidal, M., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103622 · Cited by 71
Immune responses in mildly versus critically ill COVID-19 patients
Nasrollahi, H., Talepoor, A. G., Saleh, Z., Vakili, M. E., Heydarinezhad, P., Karami, N., Noroozi, M., Meri, S., & Kalantar, K. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1077236 · Cited by 69
Host Recovery from Respiratory Viral Infection
Wei, X., Narasimhan, H., Zhu, B., & Sun, J. (2023) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101921-040450 · Cited by 67
Lombardi, A., Trombetta, E., Cattaneo, A., Castelli, V., Palomba, E., Tirone, M., Mangioni, D., Lamorte, G., Manunta, M., Prati, D., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.560330 · Cited by 66
Classical CD4 T cells as the cornerstone of antimycobacterial immunity
Morgan, J., Muskat, K., Tippalagama, R., Sette, A., Burel, J. G., & Arlehamn, C. S. L. (2021) · Immunological Reviews · doi:10.1111/imr.12963 · Cited by 70
Vikkurthi, R., Ansari, A., Pai, A. R., Jha, S. N., Sachan, S., Pandit, S., Nikam, B., Kalia, A., Jit, B. P., Parray, H. A., et al. (2022) · Nature Microbiology · doi:10.1038/s41564-022-01161-5 · Cited by 63
B cell receptor repertoire kinetics after SARS-CoV-2 infection and vaccination
Kotagiri, P., Mescia, F., Rae, W. M., Bergamaschi, L., Tuong, Z. K., Turner, L., Hunter, K., Gerber, P. P., Hosmillo, M. D. T., Hess, C., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110393 · Cited by 64
Almendro-Vázquez, P., Laguna‐Goya, R., Ruiz‐Ruigómez, M., Utrero‐Rico, A., Lalueza, A., de la Calle, G. M., Delgado, P., Ordoño, L. P., Muro, E., Vila, J. J., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1010211 · Cited by 63
Transcriptome analysis of cepharanthine against a SARS-CoV-2-related coronavirus
Li, S., Liu, W., Chen, Y., Wang, L., An, W., An, X., Song, L., Tong, Y., Fan, H., & Lu, C. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa387 · Cited by 60
Wilmore, J. R., Gaudette, B. T., Atria, D. G., Rosenthal, R. L., Reiser, S. K., Meng, W., Rosenfeld, A. M., Prak, E. T. L., & Allman, D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.791095 · Cited by 60
Self-citationQuinn, T. M., Gaughan, E. E., Bruce, A. M., Antonelli, J., O’Connor, R. A., Li, F., McNamara, S., Koch, O., Mackintosh, C., Dockrell, D. H., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103856 · Cited by 57
Vick, S. C., Frutoso, M., Mair, F., Konecny, A., Greene, E., Wolf, C. R., Logue, J. K., Franko, N., Boonyaratanakornkit, J. B., Gottardo, R., et al. (2021) · Science Advances · doi:10.1126/sciadv.abj0274 · Cited by 60
Cellular and Humoral Immune Responses in Covid-19 and Immunotherapeutic Approaches
Hasan, A., Al‐Ozairi, E., Albaqsumi, Z., Ahmad, R., & Al‐Mulla, F. (2021) · ImmunoTargets and Therapy · doi:10.2147/itt.s280706 · Cited by 56
Correlates of Vaccine-Induced Protection against SARS-CoV-2
Koch, T., Mellinghoff, S. C., Shamsrizi, P., Addo, M. M., & Dahlke, C. (2021) · Vaccines · doi:10.3390/vaccines9030238 · Cited by 59
Jedicke, N., Stankov, M. V., Cossmann, A., Dopfer‐Jablonka, A., Knuth, C., Ahrenstorf, G., Ramos, G. M., & Behrens, G. M. N. (2021) · HIV Medicine · doi:10.1111/hiv.13202 · Cited by 71
Feyaerts, D., Hedou, J. J., Gillard, J., Chen, H. M., Tsai, E. S., Peterson, L. S., Ando, K., Manohar, M., Do, E., Dhondalay, G. K., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100680 · Cited by 61
Heterogenous CD8+ T Cell Maturation and ‘Polarization’ in Acute and Convalescent COVID-19 Patients
Kudryavtsev, I. V., Arsentieva, N. A., Korobova, Z. R., Isakov, D., Rubinstein, A., Batsunov, O. K., Khamitova, I. V., Kuznetsova, R. N., Валерьевич, С. Т., Akisheva, T., et al. (2022) · Viruses · doi:10.3390/v14091906 · Cited by 56
Santopaolo, M., Gregorová, M., Hamilton, F., Arnold, D., Long, A. E., Lacey, A., Oliver, E., Halliday, A., Baum, H. E., Hamilton, K., et al. (2023) · eLife · doi:10.7554/elife.85009 · Cited by 62
How Immunosenescence and Inflammaging May Contribute to Hyperinflammatory Syndrome in COVID-19
Müller, L., & Benedetto, S. D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212539 · Cited by 66
Cell Death in Coronavirus Infections: Uncovering Its Role during COVID-19
Paolini, A., Borella, R., Biasi, S. D., Neroni, A., Mattioli, M., Tartaro, D. L., Simonini, C., Franceschini, L., Cicco, G., Piparo, A. M., et al. (2021) · Cells · doi:10.3390/cells10071585 · Cited by 57
Gamma Delta T Cells and Their Involvement in COVID-19 Virus Infections
von Massow, G., Oh, S. K. W., Lam, A. T., & Gustafsson, K. T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.741218 · Cited by 58
Савченко, А. А., Тихонова, Е. П., Kudryavtsev, I. V., Kudlay, D. A., Korsunsky, I. A., Belenyuk, V. D., & Борисов, А. Г. (2022) · Viruses · doi:10.3390/v14030646 · Cited by 55
Shachar, S. B., Barda, N., Manor, S., Israeli, S., Dagan, N., Haber, A., Carmi, S., Balicer, R., Zisser, B., & Louzoun, Y. (2021) · Journal of Clinical Immunology · doi:10.1007/s10875-021-01071-x · Cited by 62
Immunesenescence: A Predisposing Risk Factor for the Development of COVID-19?
Hazeldine, J., & Lord, J. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.573662 · Cited by 67
Zenarruzabeitia, O., Astarloa-Pando, G., Terrén, I., Orrantia, A., Pérez-Garay, R., Seijas, I., Arana, J. N., Imaz-Ayo, N., Pérez-Fernández, S., Arana‐Arri, E., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.655934 · Cited by 57
B cell contribution to immunometabolic dysfunction and impaired immune responses in obesity
Oļeiņika, K., Šlisere, B., Catalán, D., & Rosser, E. C. (2022) · Clinical & Experimental Immunology · doi:10.1093/cei/uxac079 · Cited by 58
Biological Mechanisms of COVID-19 Acute Respiratory Distress Syndrome
Matthay, M. A., Leligdowicz, A., & Liu, K. D. (2020) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202009-3629ed · Cited by 54
A comprehensive review about immune responses and exhaustion during coronavirus disease (COVID-19)
Mohammed, R. N., Tamjidifar, R., Rahman, H. S., Adili, A., Ghoreishizadeh, S., Saeedi, H., Thangavelu, L. P., Shomali, N., Aslaminabad, R., Marofi, F., et al. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-022-00856-w · Cited by 57
Byazrova, M. G., Yusubalieva, G. M., Spiridonova, A. A., Efimov, G. A., Mazurov, D. V., Baranov, K. O., Baklaushev, V. P., & Filatov, A. V. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1245 · Cited by 55
SARS-CoV-2-Associated T-Cell Responses in the Presence of Humoral Immunodeficiency
Gupta, S., Su, H., Narsai, T., & Agrawal, S. (2021) · International Archives of Allergy and Immunology · doi:10.1159/000514193 · Cited by 54
Bozzano, F. M., Dentone, C., Perrone, C., Biagio, A. D., Fenoglio, D., Parodi, A., Mikulska, M., Bruzzone, B. M., Giacobbe, D. R., Vena, A., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009448 · Cited by 52
T‐cell recovery and evidence of persistent immune activation 12 months after severe COVID ‐19
Taeschler, P., Adamo, S., Deng, Y., Cervia, C., Zurbuchen, Y., Chevrier, S., Raeber, M. E., Hasler, S., Bächli, E., Rudiger, A., et al. (2022) · Allergy · doi:10.1111/all.15372 · Cited by 53
Dengue and COVID-19: two sides of the same coin
Malavige, G. N., Jeewandara, C., & Ogg, G. S. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00833-y · Cited by 60
SARS-CoV-2 and immune-microbiome interactions: Lessons from respiratory viral infections
Cyprian, F. S., Sohail, M. U., Abdelhafez, I., Salman, S., Attique, Z., Kamareddine, L., & Al‐Asmakh, M. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.02.071 · Cited by 52
Delshad, M., Tavakolinia, N., Pourbagheri‐Sigaroodi, A., Safaroghli‐Azar, A., Bagheri, N., & Bashash, D. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107586 · Cited by 57
NK cell receptor and ligand composition influences the clearance of SARS-CoV-2
Hsieh, W.-C., Lai, E., Liu, Y., Wang, Y., Tzeng, Y.-S., Cui, L., Lai, Y., Huang, H., Huang, J., Ni, H. C., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci146408 · Cited by 49
Protective neutralizing epitopes in SARS‐CoV‐2
Liu, H., & Wilson, I. A. (2022) · Immunological Reviews · doi:10.1111/imr.13084 · Cited by 50
Differential immune responses in pregnant patients recovered from COVID-19
Chen, G., Zhang, Y., Zhang, Y., Ai, J., Yang, B., Cui, M., Liao, Q., Chen, H., Bai, H., Shang, D., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00703-3 · Cited by 59
The Robustness of Cellular Immunity Determines the Fate of SARS-CoV-2 Infection
Moga, E., Lynton‐Pons, E., & Domingo, P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.904686 · Cited by 52
Li, Y., Hook, J. S., Qing, D., Xiao, X., Chung, S. S., Mettlen, M., Xu, L., Moreland, J. G., & Agathocleous, M. (2023) · Nature Communications · doi:10.1038/s41467-023-37567-w · Cited by 54
Kumar, D., Rostad, C. A., Jaggi, P., Villacis-Nunez, D. S., Prince, C. Z., Lu, A., Hussaini, L., Nguyen, T. H., Malik, S., Ponder, L. A., et al. (2022) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2022.02.028 · Cited by 49
Self-citationChang, C., Feng, P., Wu, T.-H., Alachkar, H., Lee, K.-Y., & Chang, W. (2021) · Journal of Clinical Immunology · doi:10.1007/s10875-021-01045-z · Cited by 47
Arthur, L., Esaulova, E., Mogilenko, D. A., Tsurinov, P., Burdess, S., Laha, A., Presti, R. M., Goetz, B. D., Watson, M. A., Goss, C. W., et al. (2021) · Nature Aging · doi:10.1038/s43587-021-00067-x · Cited by 51
Shrivastava, S., Chelluboina, S., Jedge, P. P., Doke, P. P., Palkar, S. H., Mishra, A. C., & Arankalle, V. A. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.751232 · Cited by 54
Dysregulated Immune Responses in SARS-CoV-2-Infected Patients: A Comprehensive Overview
Kudryavtsev, I. V., Rubinstein, A., Головкин, А. С., Kalinina, O., Vasilyev, K., Георгиевна, Р. Л., & Isakova–Sivak, I. (2022) · Viruses · doi:10.3390/v14051082 · Cited by 49
Impaired Cellular Immunity to SARS-CoV-2 in Severe COVID-19 Patients
Ni, L., Cheng, M., Zhao, H., Feng, Y., Liu, J., Ye, F., Ye, Q., Zhu, G., Li, X., Wang, P., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.603563 · Cited by 50
High-Throughput Screening for Drug Discovery
(2022) · IntechOpen eBooks · doi:10.5772/intechopen.91075 · Cited by 45
COVID ‐19 and plasma cells: Is there long‐lived protection?*
Nguyen, D. C., Lamothe, P. A., Woodruff, M. C., Saini, A. S., Faliti, C. E., Sanz, I., & Lee, F. E.-H. (2022) · Immunological Reviews · doi:10.1111/imr.13115 · Cited by 53
Metadata
- Authors
- Kuri-Cervantes, L., Pampena, M. B., Meng, W., Rosenfeld, A. M., Ittner, C. A. G., Weisman, A. R., Agyekum, R. S., Mathew, D., Baxter, A. E., Vella, L. A., Kuthuru, O., Apostolidis, S. A., Bershaw, L., Dougherty, J., Greenplate, A. R., Pattekar, A., Kim, J., Han, N., Gouma, S., Weirick, M. E., Arevalo, C. P., Bolton, M. J., Goodwin, E. C., Anderson, E. M., Hensley, S. E., Jones, T. K., Mangalmurti, N. S., Luning Prak, E. T., Wherry, E. J., Meyer, N. J., & Betts, M. R.
- Affiliations
- University of Pennsylvania (US)
- Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
- Department of Pathology and Laboratory Medicine, Perelman School of Medicine, Philadelphia, PA 19104, USA.
- Children's Hospital of Philadelphia (US)
- Hospital of the University of Pennsylvania (US)
- Parker Institute for Cancer Immunotherapy (US)
- Corresponding author
- Kuri-Cervantes, Leticia
- Wherry, E. John
- Meyer, Nuala J.
- Betts, Michael R.
- ORCID
- Kuri-Cervantes, Leticia
- Pampena, Maria Betina
- Meng, Wenzhao
- Rosenfeld, Aaron M.
- Weisman, Ariel R.
- Agyekum, Roseline S.
- Mathew, Divij
- Baxter, Amy E.
- Vella, Laura A.
- Kuthuru, Oliva
- Apostolidis, Sokratis A.
- Bershaw, Luanne
- Dougherty, Jeanette
- Greenplate, Allison R.
- Pattekar, Ajinkya
- Kim, Justin
- Han, Nicholas
- Gouma, Sigrid
- Weirick, Madison E.
- Arevalo, Claudia P.
- Bolton, Marcus J.
- Anderson, Elizabeth M.
- Hensley, Scott E.
- Jones, Tiffanie K.
- Mangalmurti, Nilam S.
- Luning Prak, Eline T.
- Wherry, E. John
- Meyer, Nuala J.
- Betts, Michael R.
- Venue
- Science Immunology
- Published
- 2020-07-03
- Volume
- 5
- Issue
- 49
- ISSN
- 2470-9468 (ISSN-L)
- PMC
- PMC7402634
- OpenAlex
- W3042587425
- Cited by
- 723
- References
- 107
- Citations by year
- 2026: 15 · 2025: 27 · 2024: 63 · 2023: 101 · 2022: 182 · 2021: 251 · 2020: 83
- FWCI
- 20.38
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- Locations
- Science Immunology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (HL137006, HL137915, AI144288, P30-CA016520, AI105343, AI115712, AI117950, AI108545, AI082630, CA210944, T32 CA009140.)
- National Institute of Allergy and Infectious Diseases (AI136660)
- Topics
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Immunology and Microbiology › Immunology › Inflammation biomarkers and pathways
- Keywords
- severe COVID-19, SARS-CoV-2, immune perturbation, hyperinflammation, T cell activation, innate lymphoid cells, granulocytes, neutrophil-to-lymphocyte ratio, prognostic factors, organ failure
- MeSH terms
- Betacoronavirus, COVID-19, SARS-CoV-2, Aged, Female, Humans, Immunity, Innate, Immunologic Memory, Lymphocyte Activation, Male, Middle Aged, Neutrophils, Pneumonia, Viral, T-Lymphocytes, B-Lymphocyte Subsets, Cytokines, Coronavirus Infections, Lymphocyte Count, Pandemics, Clonal Selection, Antigen-Mediated
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.